Clinical Trial Update: The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and immunogenicity of a single dose of V114, PNEUMOVAX 23, or PREVNAR 13 in adults 50+; results completed with pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)
• Prevnar 13 (pneumococcal conjugate vaccine)
• V114 (15-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections | Phase 2 | Status: COMPLETED | Results posted: 2018-12-13